PROCEPT BioRobotics (Nasdaq: PRCT), today announced the international expansion of the HYDROS Robotic System, the company’s next-generation platform for delivering Aquablation therapy to treat benign ...

Procept BioRobotics today announced the international rollout of its next-generation Hydros robotic system for Aquablation ...

PROCEPT BioRobotics (NASDAQ:PRCT) used its 2026 Analyst Day to outline what management characterized as a large, underpenetrated opportunity in benign prostatic hyperplasia (BPH), a developing ...

Truist lowered the firm’s price target on Procept BioRobotics (PRCT) to $30 from $47 but keeps a Buy rating on the shares.

Jefferies initiated coverage of Procept BioRobotics (PRCT) with a Hold rating and $95 price target The firm’s checks suggest the Hydros system launch could catalyze a replacement cycle among systems ...

Detailed price information for Procept Biorobotics Corp (PRCT-Q) from The Globe and Mail including charting and trades.

PROCEPT BioRobotics PRCT is gearing up to announce its quarterly earnings on Wednesday, 2025-08-06. Here's a quick overview of what investors should know before the release. Analysts are estimating ...

Director Antal Rohit Desai of PROCEPT BioRobotics Corp (NASDAQ:PRCT) reported purchasing shares of common stock in multiple transactions between March 5 and March 9, 2026. The total value of these ...

SAN JOSE, Calif., Oct. 09, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing ...

PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT BioRobotics develops, manufactures and sells the ...

SAN JOSE, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (PRCT) ® Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative ...